{"transactions":[{"id":1121370,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-05T20:23:08.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":18111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."}],"balance_after":18111,"derivative":{"exercise_price":13.93,"expiration_date":"2035-06-03","underlying":"Common Stock","underlying_shares":18111},"source":{"system":"sec-edgar","filing":"0001714899-25-000136","document":"wk-form4_1749154932.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000136/wk-form4_1749154932.xml","form_type":"4"}},{"id":1121369,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-05T20:23:08.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":6037,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 6,037 unvested RSUs."}],"balance_after":1886576,"source":{"system":"sec-edgar","filing":"0001714899-25-000136","document":"wk-form4_1749154932.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489925000136/wk-form4_1749154932.xml","form_type":"4"}},{"id":1492401,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-04T22:31:58.000Z","date":"2024-05-31","kind":"grant","planned":false,"acquired":true,"shares":17901,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."}],"balance_after":17901,"derivative":{"exercise_price":18.56,"expiration_date":"2034-05-31","underlying":"Common Stock","underlying_shares":17901},"source":{"system":"sec-edgar","filing":"0001714899-24-000140","document":"wk-form4_1717540308.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000140/wk-form4_1717540308.xml","form_type":"4"}},{"id":1492400,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-04T22:31:58.000Z","date":"2024-05-31","kind":"grant","planned":false,"acquired":true,"shares":5967,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 5,967 unvested RSUs."}],"balance_after":1880539,"source":{"system":"sec-edgar","filing":"0001714899-24-000140","document":"wk-form4_1717540308.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000140/wk-form4_1717540308.xml","form_type":"4"}},{"id":1867189,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-05T22:06:39.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":12649,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."}],"balance_after":12649,"derivative":{"exercise_price":30.92,"expiration_date":"2033-06-01","underlying":"Common Stock","underlying_shares":12649},"source":{"system":"sec-edgar","filing":"0001714899-23-000099","document":"wk-form4_1686002790.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000099/wk-form4_1686002790.xml","form_type":"4"}},{"id":1867188,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-05T22:06:39.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":4216,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's\nnext annual meeting of stockholders occurring after the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 4,216 unvested RSUs."}],"balance_after":1874572,"source":{"system":"sec-edgar","filing":"0001714899-23-000099","document":"wk-form4_1686002790.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489923000099/wk-form4_1686002790.xml","form_type":"4"}},{"id":2064237,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-01-05T21:16:35.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":1929,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant."}],"balance_after":1929,"derivative":{"exercise_price":725.89,"expiration_date":"2033-01-03","underlying":"Common Stock","underlying_shares":1929},"source":{"system":"sec-edgar","filing":"0001883850-23-000015","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000015/edgardoc.xml","form_type":"4"}},{"id":2064236,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-05T21:16:35.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":165,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock."}],"balance_after":2434,"source":{"system":"sec-edgar","filing":"0001883850-23-000015","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000015/edgardoc.xml","form_type":"4"}},{"id":2064235,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-01-05T21:16:18.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":1929,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant."}],"balance_after":1929,"derivative":{"exercise_price":725.89,"expiration_date":"2033-01-03","underlying":"Common Stock","underlying_shares":1929},"source":{"system":"sec-edgar","filing":"0001883850-23-000014","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000014/edgardoc.xml","form_type":"4"}},{"id":2064234,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-05T21:16:18.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":165,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock."}],"balance_after":2434,"source":{"system":"sec-edgar","filing":"0001883850-23-000014","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385023000014/edgardoc.xml","form_type":"4"}},{"id":2103477,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-29T00:30:02.000Z","date":"2022-11-23","kind":"sale","acquired":false,"shares":20000,"price":30.48,"value":609600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $30.15 to $31.09 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 5,986 unvested restricted stock units."}],"balance_after":1870356,"source":{"system":"sec-edgar","filing":"0001714899-22-000148","document":"wf-form4_166968178535428.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489922000148/wf-form4_166968178535428.xml","form_type":"4"}},{"id":2125738,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-03T21:37:33.000Z","date":"2022-11-02","kind":"sale","acquired":false,"shares":11252,"price":30.33,"value":341273.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $30.00 to $30.90 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 5,986 unvested restricted stock units."}],"balance_after":1890356,"source":{"system":"sec-edgar","filing":"0001714899-22-000146","document":"wf-form4_166751143725460.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489922000146/wf-form4_166751143725460.xml","form_type":"4"}},{"id":2125737,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-03T21:37:33.000Z","date":"2022-11-01","kind":"sale","acquired":false,"shares":8748,"price":30.2,"value":264189.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $30.00 to $30.48 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 5,986 unvested restricted stock units."}],"balance_after":1901608,"source":{"system":"sec-edgar","filing":"0001714899-22-000146","document":"wf-form4_166751143725460.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489922000146/wf-form4_166751143725460.xml","form_type":"4"}},{"id":2148161,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-10-03T20:05:44.000Z","date":"2022-10-03","kind":"exercise","acquired":false,"shares":3612,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant."}],"balance_after":0,"derivative":{"exercise_price":413.33,"expiration_date":"2025-01-02","underlying":"Common Stock","underlying_shares":3612},"source":{"system":"sec-edgar","filing":"0001883850-22-000072","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000072/edgardoc.xml","form_type":"4"}},{"id":2148160,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-10-03T20:05:44.000Z","date":"2022-09-30","kind":"exercise","acquired":false,"shares":3428,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant."}],"balance_after":3612,"derivative":{"exercise_price":413.33,"expiration_date":"2025-01-02","underlying":"Common Stock","underlying_shares":3428},"source":{"system":"sec-edgar","filing":"0001883850-22-000072","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000072/edgardoc.xml","form_type":"4"}},{"id":2148159,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-10-03T20:05:44.000Z","date":"2022-09-29","kind":"exercise","acquired":false,"shares":3798,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant."}],"balance_after":7040,"derivative":{"exercise_price":413.33,"expiration_date":"2025-01-02","underlying":"Common Stock","underlying_shares":3798},"source":{"system":"sec-edgar","filing":"0001883850-22-000072","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000072/edgardoc.xml","form_type":"4"}},{"id":2148158,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-03T20:05:44.000Z","date":"2022-10-03","kind":"sale","acquired":false,"shares":3612,"price":718,"value":2593416.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":2269,"source":{"system":"sec-edgar","filing":"0001883850-22-000072","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000072/edgardoc.xml","form_type":"4"}},{"id":2148157,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-03T20:05:44.000Z","date":"2022-10-03","kind":"exercise","acquired":true,"shares":3612,"price":413.33,"value":1492947.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":5881,"source":{"system":"sec-edgar","filing":"0001883850-22-000072","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000072/edgardoc.xml","form_type":"4"}},{"id":2148156,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-03T20:05:44.000Z","date":"2022-09-30","kind":"sale","acquired":false,"shares":3428,"price":698,"value":2392744.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":2269,"source":{"system":"sec-edgar","filing":"0001883850-22-000072","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000072/edgardoc.xml","form_type":"4"}},{"id":2148155,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-03T20:05:44.000Z","date":"2022-09-30","kind":"exercise","acquired":true,"shares":3428,"price":413.33,"value":1416895.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":5697,"source":{"system":"sec-edgar","filing":"0001883850-22-000072","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000072/edgardoc.xml","form_type":"4"}},{"id":2148154,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-03T20:05:44.000Z","date":"2022-09-29","kind":"sale","acquired":false,"shares":20,"price":704.83,"value":14096.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":2269,"source":{"system":"sec-edgar","filing":"0001883850-22-000072","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000072/edgardoc.xml","form_type":"4"}},{"id":2148153,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-03T20:05:44.000Z","date":"2022-09-29","kind":"sale","acquired":false,"shares":16,"price":702.36,"value":11237.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":2289,"source":{"system":"sec-edgar","filing":"0001883850-22-000072","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000072/edgardoc.xml","form_type":"4"}},{"id":2148152,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-03T20:05:44.000Z","date":"2022-09-29","kind":"sale","acquired":false,"shares":80,"price":699.82,"value":55985.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":2305,"source":{"system":"sec-edgar","filing":"0001883850-22-000072","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000072/edgardoc.xml","form_type":"4"}},{"id":2148151,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-03T20:05:44.000Z","date":"2022-09-29","kind":"sale","acquired":false,"shares":208,"price":698.44,"value":145275.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents volume-weighted average price of sales of 208 shares of Company stock on September 29, 2022 at prices ranging from $698.19 to $698.71. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 29, 2022 at each separate price."}],"balance_after":2385,"source":{"system":"sec-edgar","filing":"0001883850-22-000072","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000072/edgardoc.xml","form_type":"4"}},{"id":2148150,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-03T20:05:44.000Z","date":"2022-09-29","kind":"sale","acquired":false,"shares":160,"price":697.29,"value":111566.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents volume-weighted average price of sales of 160 shares of Company stock on September 29, 2022 at prices ranging from $697.10 to $697.66. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 29, 2022 at each separate price."}],"balance_after":2593,"source":{"system":"sec-edgar","filing":"0001883850-22-000072","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000072/edgardoc.xml","form_type":"4"}},{"id":2148149,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-03T20:05:44.000Z","date":"2022-09-29","kind":"sale","acquired":false,"shares":85,"price":696.13,"value":59171.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents volume-weighted average price of sales of 85 shares of Company stock on September 29, 2022 at prices ranging from $696.03 to $696.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 29, 2022 at each separate price."}],"balance_after":2753,"source":{"system":"sec-edgar","filing":"0001883850-22-000072","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000072/edgardoc.xml","form_type":"4"}},{"id":2148148,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-03T20:05:44.000Z","date":"2022-09-29","kind":"sale","acquired":false,"shares":554,"price":691.59,"value":383140.86,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents volume-weighted average price of sales of 554 shares of Company stock on September 29, 2022 at prices ranging from $691.29 to $691.72. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 29, 2022 at each separate price."}],"balance_after":2838,"source":{"system":"sec-edgar","filing":"0001883850-22-000072","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000072/edgardoc.xml","form_type":"4"}},{"id":2148147,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-03T20:05:44.000Z","date":"2022-09-29","kind":"sale","acquired":false,"shares":692,"price":690.65,"value":477929.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents volume-weighted average price of sales of 692 shares of Company stock on September 29, 2022 at prices ranging from $690.06 to $690.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 29, 2022 at each separate price."}],"balance_after":3392,"source":{"system":"sec-edgar","filing":"0001883850-22-000072","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000072/edgardoc.xml","form_type":"4"}},{"id":2148146,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-03T20:05:44.000Z","date":"2022-09-29","kind":"sale","acquired":false,"shares":1009,"price":689.56,"value":695766.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents volume-weighted average price of sales of 1,009 shares of Company stock on September 29, 2022 at prices ranging from $689.07 to $689.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 29, 2022 at each separate price."}],"balance_after":4084,"source":{"system":"sec-edgar","filing":"0001883850-22-000072","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000072/edgardoc.xml","form_type":"4"}},{"id":2148145,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-03T20:05:44.000Z","date":"2022-09-29","kind":"sale","acquired":false,"shares":637,"price":688.71,"value":438708.27,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents volume-weighted average price of sales of 637 shares of Company stock on September 29, 2022 at prices ranging from $688.08 to $688.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 29, 2022 at each separate price."}],"balance_after":5093,"source":{"system":"sec-edgar","filing":"0001883850-22-000072","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000072/edgardoc.xml","form_type":"4"}},{"id":2148144,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-03T20:05:44.000Z","date":"2022-09-29","kind":"sale","acquired":false,"shares":321,"price":687.9,"value":220815.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents volume-weighted average price of sales of 321 shares of Company stock on September 29, 2022 at prices ranging from $687.05 to $687.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 29, 2022 at each separate price."}],"balance_after":5730,"source":{"system":"sec-edgar","filing":"0001883850-22-000072","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000072/edgardoc.xml","form_type":"4"}},{"id":2148143,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-03T20:05:44.000Z","date":"2022-09-29","kind":"sale","acquired":false,"shares":16,"price":686.89,"value":10990.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 16 shares of Company stock on September 29, 2022 at prices ranging from $686.89 to $686.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 29, 2022 at each separate price."}],"balance_after":6051,"source":{"system":"sec-edgar","filing":"0001883850-22-000072","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000072/edgardoc.xml","form_type":"4"}},{"id":2148142,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-03T20:05:44.000Z","date":"2022-09-29","kind":"exercise","acquired":true,"shares":3798,"price":413.33,"value":1569827.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":6067,"source":{"system":"sec-edgar","filing":"0001883850-22-000072","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000072/edgardoc.xml","form_type":"4"}},{"id":2148708,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-30T20:50:54.000Z","date":"2022-09-28","kind":"sale","acquired":false,"shares":4423,"price":31.08,"value":137466.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $31.00 to $31.31 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 5,986 unvested restricted stock units."}],"balance_after":1910356,"source":{"system":"sec-edgar","filing":"0001714899-22-000133","document":"wf-form4_166457103687475.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489922000133/wf-form4_166457103687475.xml","form_type":"4"}},{"id":2148707,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-09-30T20:50:54.000Z","date":"2022-09-28","kind":"sale","acquired":false,"shares":15577,"price":30.74,"value":478836.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $30.00 to $30.99 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 5,986 unvested restricted stock units."}],"balance_after":1914779,"source":{"system":"sec-edgar","filing":"0001714899-22-000133","document":"wf-form4_166457103687475.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489922000133/wf-form4_166457103687475.xml","form_type":"4"}},{"id":2173956,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-25T22:11:10.000Z","date":"2022-08-23","kind":"sale","acquired":false,"shares":100,"price":32.43,"value":3243.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 5,986 unvested restricted stock units."}],"balance_after":1930356,"source":{"system":"sec-edgar","filing":"0001714899-22-000131","document":"wf-form4_166146545134466.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489922000131/wf-form4_166146545134466.xml","form_type":"4"}},{"id":2173955,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-25T22:11:10.000Z","date":"2022-08-23","kind":"sale","acquired":false,"shares":19900,"price":31.61,"value":629039.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $31.33 to $32.31 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 5,986 unvested restricted stock units."}],"balance_after":1930456,"source":{"system":"sec-edgar","filing":"0001714899-22-000131","document":"wf-form4_166146545134466.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489922000131/wf-form4_166146545134466.xml","form_type":"4"}},{"id":2201359,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-27T22:49:15.000Z","date":"2022-07-25","kind":"sale","acquired":false,"shares":200,"price":36.15,"value":7230.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $36.03 to $36.27 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 5,986 unvested restricted stock units."}],"balance_after":1950356,"source":{"system":"sec-edgar","filing":"0001714899-22-000109","document":"wf-form4_165896213456047.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489922000109/wf-form4_165896213456047.xml","form_type":"4"}},{"id":2201358,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-27T22:49:15.000Z","date":"2022-07-25","kind":"sale","acquired":false,"shares":19800,"price":35.6,"value":704880.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $35.02 to $36.01 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 5,986 unvested restricted stock units."}],"balance_after":1950556,"source":{"system":"sec-edgar","filing":"0001714899-22-000109","document":"wf-form4_165896213456047.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489922000109/wf-form4_165896213456047.xml","form_type":"4"}},{"id":2220196,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-28T19:07:44.000Z","date":"2022-03-23","kind":"sale","acquired":false,"shares":11598,"price":34.14,"value":395955.72,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"For this amended Form 4 filing the only change is to add the signature."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $33.76 to $34.69 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 2,074 restricted stock units."}],"balance_after":2024370,"source":{"system":"sec-edgar","filing":"0001714899-22-000101","document":"wf-form4a_165644324155351.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489922000101/wf-form4a_165644324155351.xml","form_type":"4/A","original_submission_date":"2022-03-25"}},{"id":2220195,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-28T19:07:44.000Z","date":"2022-03-23","kind":"sale","acquired":false,"shares":8402,"price":33.4,"value":280626.8,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"For this amended Form 4 filing the only change is to add the signature."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $32.76 to $33.75 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 2,074 restricted stock units."}],"balance_after":2035968,"source":{"system":"sec-edgar","filing":"0001714899-22-000101","document":"wf-form4a_165644324155351.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489922000101/wf-form4a_165644324155351.xml","form_type":"4/A","original_submission_date":"2022-03-25"}},{"id":2221177,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-28T00:54:29.000Z","date":"2022-06-24","kind":"disposition_to_issuer","acquired":false,"shares":6766,"price":31.0761,"value":210260.8926,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $31.00 to $31.19 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 5,986 unvested restricted stock units."}],"balance_after":1970356,"source":{"system":"sec-edgar","filing":"0001628280-22-018113","document":"wf-form4_165637764875845.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000162828022018113/wf-form4_165637764875845.xml","form_type":"4"}},{"id":2221176,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-28T00:54:29.000Z","date":"2022-06-24","kind":"disposition_to_issuer","acquired":false,"shares":39984,"price":30.5299,"value":1220707.5216,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $30.00 to $30.99 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 5,986 unvested restricted stock units."}],"balance_after":1977122,"source":{"system":"sec-edgar","filing":"0001628280-22-018113","document":"wf-form4_165637764875845.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000162828022018113/wf-form4_165637764875845.xml","form_type":"4"}},{"id":2221175,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-28T00:54:29.000Z","date":"2022-06-23","kind":"disposition_to_issuer","acquired":false,"shares":13250,"price":31.1001,"value":412076.325,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $30.00 to $30.19 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 5,986 unvested restricted stock units."}],"balance_after":2017106,"source":{"system":"sec-edgar","filing":"0001628280-22-018113","document":"wf-form4_165637764875845.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000162828022018113/wf-form4_165637764875845.xml","form_type":"4"}},{"id":2242448,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-07T00:09:21.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":17959,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."}],"balance_after":17959,"derivative":{"exercise_price":24.27,"expiration_date":"2032-06-02","underlying":"Common Stock","underlying_shares":17959},"source":{"system":"sec-edgar","filing":"0001714899-22-000096","document":"wf-form4_165456054624289.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489922000096/wf-form4_165456054624289.xml","form_type":"4"}},{"id":2242447,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-07T00:09:21.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":5986,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share is represented by a Restricted Stock Unit (\"RSU\") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 5,986 unvested restricted stock units."}],"balance_after":2030356,"source":{"system":"sec-edgar","filing":"0001714899-22-000096","document":"wf-form4_165456054624289.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489922000096/wf-form4_165456054624289.xml","form_type":"4"}},{"id":2317765,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-25T21:57:33.000Z","date":"2022-03-23","kind":"sale","acquired":false,"shares":11598,"price":34.14,"value":395955.72,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $33.76 to $34.69 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2,074 restricted stock units."}],"balance_after":2024370,"source":{"system":"sec-edgar","filing":"0001714899-22-000061","document":"wf-form4_164824543669895.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489922000061/wf-form4_164824543669895.xml","form_type":"4"}},{"id":2317764,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-25T21:57:33.000Z","date":"2022-03-23","kind":"sale","acquired":false,"shares":8402,"price":33.4,"value":280626.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $32.76 to $33.75 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2,074 restricted stock units."}],"balance_after":2035968,"source":{"system":"sec-edgar","filing":"0001714899-22-000061","document":"wf-form4_164824543669895.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489922000061/wf-form4_164824543669895.xml","form_type":"4"}},{"id":2320491,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-03-23T20:01:42.000Z","date":"2022-03-21","kind":"exercise","acquired":false,"shares":7439,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant."}],"balance_after":0,"derivative":{"exercise_price":380.95,"expiration_date":"2028-01-02","underlying":"Common Stock","underlying_shares":7439},"source":{"system":"sec-edgar","filing":"0001708138-22-000027","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813822000027/edgardoc.xml","form_type":"4"}},{"id":2320490,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-23T20:01:42.000Z","date":"2022-03-21","kind":"sale","acquired":false,"shares":7439,"price":690,"value":5132910.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":2269,"source":{"system":"sec-edgar","filing":"0001708138-22-000027","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813822000027/edgardoc.xml","form_type":"4"}},{"id":2320489,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-23T20:01:42.000Z","date":"2022-03-21","kind":"exercise","acquired":true,"shares":7439,"price":380.95,"value":2833887.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":9708,"source":{"system":"sec-edgar","filing":"0001708138-22-000027","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813822000027/edgardoc.xml","form_type":"4"}},{"id":2325501,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-03-18T20:05:21.000Z","date":"2022-03-17","kind":"exercise","acquired":false,"shares":7830,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant."}],"balance_after":0,"derivative":{"exercise_price":376.69,"expiration_date":"2027-01-03","underlying":"Common Stock","underlying_shares":7830},"source":{"system":"sec-edgar","filing":"0001708138-22-000020","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813822000020/edgardoc.xml","form_type":"4"}},{"id":2325500,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-03-18T20:05:21.000Z","date":"2022-03-16","kind":"exercise","acquired":false,"shares":4361,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant."}],"balance_after":0,"derivative":{"exercise_price":374.12,"expiration_date":"2030-01-02","underlying":"Common Stock","underlying_shares":4361},"source":{"system":"sec-edgar","filing":"0001708138-22-000020","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813822000020/edgardoc.xml","form_type":"4"}},{"id":2325499,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-18T20:05:21.000Z","date":"2022-03-17","kind":"sale","acquired":false,"shares":7830,"price":680,"value":5324400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":2269,"source":{"system":"sec-edgar","filing":"0001708138-22-000020","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813822000020/edgardoc.xml","form_type":"4"}},{"id":2325498,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-18T20:05:21.000Z","date":"2022-03-17","kind":"exercise","acquired":true,"shares":7830,"price":376.69,"value":2949482.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":10099,"source":{"system":"sec-edgar","filing":"0001708138-22-000020","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813822000020/edgardoc.xml","form_type":"4"}},{"id":2325497,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-18T20:05:21.000Z","date":"2022-03-16","kind":"sale","acquired":false,"shares":4361,"price":675,"value":2943675.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":2269,"source":{"system":"sec-edgar","filing":"0001708138-22-000020","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813822000020/edgardoc.xml","form_type":"4"}},{"id":2325496,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-18T20:05:21.000Z","date":"2022-03-16","kind":"exercise","acquired":true,"shares":4361,"price":374.12,"value":1631537.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":6630,"source":{"system":"sec-edgar","filing":"0001708138-22-000020","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813822000020/edgardoc.xml","form_type":"4"}},{"id":2388650,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-02-18T01:25:24.000Z","date":"2021-12-13","kind":"gift","acquired":false,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction involved a gift of securities by the Reporting Person.  Disposition price is not applicable as this transaction was a bona fide gift."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2,074 restricted stock units."}],"balance_after":2044370,"source":{"system":"sec-edgar","filing":"0001714899-22-000043","document":"wf-form5_164514750112269.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489922000043/wf-form5_164514750112269.xml","form_type":"5"}},{"id":2445834,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-01-05T21:23:37.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":2707,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant."}],"balance_after":2707,"derivative":{"exercise_price":625.6,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":2707},"source":{"system":"sec-edgar","filing":"0001883850-22-000008","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000008/edgardoc.xml","form_type":"4"}},{"id":2445833,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-05T21:23:37.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":191,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock."}],"balance_after":2269,"source":{"system":"sec-edgar","filing":"0001883850-22-000008","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000188385022000008/edgardoc.xml","form_type":"4"}},{"id":2456225,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-31T02:59:44.000Z","date":"2021-12-30","kind":"sale","acquired":false,"shares":800,"price":45.72,"value":36576.0,"ownership":{"direct":false,"nature":"The Tessier-Lavigne/Hynes Irrevocable Trust 3"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F17","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $45.67 to $45.80 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 3, for which the Reporting Person serves as trustee."}],"balance_after":78848,"source":{"system":"sec-edgar","filing":"0001714899-21-000117","document":"wf-form4_164091956763788.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489921000117/wf-form4_164091956763788.xml","form_type":"4"}},{"id":2456224,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-31T02:59:44.000Z","date":"2021-12-30","kind":"sale","acquired":false,"shares":6002,"price":45.31,"value":271950.62,"ownership":{"direct":false,"nature":"The Tessier-Lavigne/Hynes Irrevocable Trust 3"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $44.65 to $45.62 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 3, for which the Reporting Person serves as trustee."}],"balance_after":79648,"source":{"system":"sec-edgar","filing":"0001714899-21-000117","document":"wf-form4_164091956763788.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489921000117/wf-form4_164091956763788.xml","form_type":"4"}},{"id":2456223,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-31T02:59:44.000Z","date":"2021-12-29","kind":"sale","acquired":false,"shares":10704,"price":43.88,"value":469691.52,"ownership":{"direct":false,"nature":"The Tessier-Lavigne/Hynes Irrevocable Trust 3"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $43.50 to $44.09 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 3, for which the Reporting Person serves as trustee."}],"balance_after":85650,"source":{"system":"sec-edgar","filing":"0001714899-21-000117","document":"wf-form4_164091956763788.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489921000117/wf-form4_164091956763788.xml","form_type":"4"}},{"id":2456222,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-31T02:59:44.000Z","date":"2021-12-28","kind":"sale","acquired":false,"shares":3646,"price":44.37,"value":161773.02,"ownership":{"direct":false,"nature":"The Tessier-Lavigne/Hynes Irrevocable Trust 3"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $44.18 to $44.63 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 3, for which the Reporting Person serves as trustee."}],"balance_after":96354,"source":{"system":"sec-edgar","filing":"0001714899-21-000117","document":"wf-form4_164091956763788.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489921000117/wf-form4_164091956763788.xml","form_type":"4"}},{"id":2456221,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-31T02:59:44.000Z","date":"2021-10-04","kind":"gift","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"The Tessier-Lavigne/Hynes Irrevocable Trust 3"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction involved a gift of securities by the Reporting Person. Disposition price is not applicable as this transaction was a bona fide gift."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 3, for which the Reporting Person serves as trustee."}],"balance_after":100000,"source":{"system":"sec-edgar","filing":"0001714899-21-000117","document":"wf-form4_164091956763788.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489921000117/wf-form4_164091956763788.xml","form_type":"4"}},{"id":2456220,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-31T02:59:44.000Z","date":"2021-12-30","kind":"sale","acquired":false,"shares":900,"price":45.71,"value":41139.0,"ownership":{"direct":false,"nature":"The Tessier-Lavigne/Hynes Irrevocable Trust 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $45.66 to $45.77 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 2, for which the Reporting Person serves as trustee."}],"balance_after":79173,"source":{"system":"sec-edgar","filing":"0001714899-21-000117","document":"wf-form4_164091956763788.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489921000117/wf-form4_164091956763788.xml","form_type":"4"}},{"id":2456219,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-31T02:59:44.000Z","date":"2021-12-30","kind":"sale","acquired":false,"shares":5625,"price":45.31,"value":254868.75,"ownership":{"direct":false,"nature":"The Tessier-Lavigne/Hynes Irrevocable Trust 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $44.65 to $45.63 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 2, for which the Reporting Person serves as trustee."}],"balance_after":80073,"source":{"system":"sec-edgar","filing":"0001714899-21-000117","document":"wf-form4_164091956763788.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489921000117/wf-form4_164091956763788.xml","form_type":"4"}},{"id":2456218,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-31T02:59:44.000Z","date":"2021-12-29","kind":"sale","acquired":false,"shares":10700,"price":43.87,"value":469409.0,"ownership":{"direct":false,"nature":"The Tessier-Lavigne/Hynes Irrevocable Trust 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $43.51 to $44.07 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 2, for which the Reporting Person serves as trustee."}],"balance_after":85698,"source":{"system":"sec-edgar","filing":"0001714899-21-000117","document":"wf-form4_164091956763788.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489921000117/wf-form4_164091956763788.xml","form_type":"4"}},{"id":2456217,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-31T02:59:44.000Z","date":"2021-12-28","kind":"sale","acquired":false,"shares":3602,"price":44.38,"value":159856.76,"ownership":{"direct":false,"nature":"The Tessier-Lavigne/Hynes Irrevocable Trust 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $44.19 to $44.64 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 2, for which the Reporting Person serves as trustee."}],"balance_after":96398,"source":{"system":"sec-edgar","filing":"0001714899-21-000117","document":"wf-form4_164091956763788.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489921000117/wf-form4_164091956763788.xml","form_type":"4"}},{"id":2456216,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-31T02:59:44.000Z","date":"2021-10-04","kind":"gift","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"The Tessier-Lavigne/Hynes Irrevocable Trust 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction involved a gift of securities by the Reporting Person. Disposition price is not applicable as this transaction was a bona fide gift."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 2, for which the Reporting Person serves as trustee."}],"balance_after":100000,"source":{"system":"sec-edgar","filing":"0001714899-21-000117","document":"wf-form4_164091956763788.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489921000117/wf-form4_164091956763788.xml","form_type":"4"}},{"id":2456215,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-31T02:59:44.000Z","date":"2021-12-30","kind":"sale","acquired":false,"shares":3377,"price":45.59,"value":153957.43,"ownership":{"direct":false,"nature":"The Tessier-Lavigne/Hynes Irrevocable Trust 1"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $45.42 to $45.81 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 1, for which the Reporting Person serves as trustee."}],"balance_after":78848,"source":{"system":"sec-edgar","filing":"0001714899-21-000117","document":"wf-form4_164091956763788.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489921000117/wf-form4_164091956763788.xml","form_type":"4"}},{"id":2456214,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-31T02:59:44.000Z","date":"2021-12-30","kind":"sale","acquired":false,"shares":3343,"price":45.13,"value":150869.59,"ownership":{"direct":false,"nature":"The Tessier-Lavigne/Hynes Irrevocable Trust 1"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $44.42 to $45.41 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 1, for which the Reporting Person serves as trustee."}],"balance_after":82225,"source":{"system":"sec-edgar","filing":"0001714899-21-000117","document":"wf-form4_164091956763788.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489921000117/wf-form4_164091956763788.xml","form_type":"4"}},{"id":2456213,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-31T02:59:44.000Z","date":"2021-12-29","kind":"sale","acquired":false,"shares":10700,"price":43.88,"value":469516.0,"ownership":{"direct":false,"nature":"The Tessier-Lavigne/Hynes Irrevocable Trust 1"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $43.50 to $44.07 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 1, for which the Reporting Person serves as trustee."}],"balance_after":85568,"source":{"system":"sec-edgar","filing":"0001714899-21-000117","document":"wf-form4_164091956763788.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489921000117/wf-form4_164091956763788.xml","form_type":"4"}},{"id":2456212,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-31T02:59:44.000Z","date":"2021-12-28","kind":"sale","acquired":false,"shares":3732,"price":44.37,"value":165588.84,"ownership":{"direct":false,"nature":"The Tessier-Lavigne/Hynes Irrevocable Trust 1"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $44.19 to $44.74 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 1, for which the Reporting Person serves as trustee."}],"balance_after":96268,"source":{"system":"sec-edgar","filing":"0001714899-21-000117","document":"wf-form4_164091956763788.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489921000117/wf-form4_164091956763788.xml","form_type":"4"}},{"id":2456211,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-31T02:59:44.000Z","date":"2021-10-04","kind":"gift","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"The Tessier-Lavigne/Hynes Irrevocable Trust 1"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction involved a gift of securities by the Reporting Person. Disposition price is not applicable as this transaction was a bona fide gift."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by The Tessier-Lavigne/Hynes Irrevocable Trust 1, for which the Reporting Person serves as trustee."}],"balance_after":100000,"source":{"system":"sec-edgar","filing":"0001714899-21-000117","document":"wf-form4_164091956763788.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489921000117/wf-form4_164091956763788.xml","form_type":"4"}},{"id":2456210,"issuer":{"id":1735,"kind":"organization","name":"Denali Therapeutics Inc.","symbol":"DNLI"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-31T02:59:44.000Z","date":"2021-10-04","kind":"gift","acquired":false,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction involved a gift of securities by the Reporting Person. Disposition price is not applicable as this transaction was a bona fide gift."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2,074 restricted stock units."}],"balance_after":2244370,"source":{"system":"sec-edgar","filing":"0001714899-21-000117","document":"wf-form4_164091956763788.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489921000117/wf-form4_164091956763788.xml","form_type":"4"}},{"id":2477947,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2021-12-10T22:41:13.000Z","date":"2021-12-09","kind":"exercise","acquired":false,"shares":3784,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant."}],"balance_after":0,"derivative":{"exercise_price":371.4,"expiration_date":"2029-01-02","underlying":"Common Stock","underlying_shares":3784},"source":{"system":"sec-edgar","filing":"0001237899-21-000027","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000123789921000027/edgardoc.xml","form_type":"4"}},{"id":2477946,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-10T22:41:13.000Z","date":"2021-12-09","kind":"sale","acquired":false,"shares":3784,"price":665,"value":2516360.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":2078,"source":{"system":"sec-edgar","filing":"0001237899-21-000027","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000123789921000027/edgardoc.xml","form_type":"4"}},{"id":2477945,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-10T22:41:13.000Z","date":"2021-12-09","kind":"exercise","acquired":true,"shares":3784,"price":371.4,"value":1405377.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":5862,"source":{"system":"sec-edgar","filing":"0001237899-21-000027","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000123789921000027/edgardoc.xml","form_type":"4"}},{"id":2570083,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2021-09-15T20:02:17.000Z","date":"2021-09-13","kind":"exercise","acquired":false,"shares":4250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F17","text":"The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant."}],"balance_after":0,"derivative":{"exercise_price":273.67,"expiration_date":"2024-01-02","underlying":"Common Stock","underlying_shares":4250},"source":{"system":"sec-edgar","filing":"0001708138-21-000080","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000080/edgardoc.xml","form_type":"4"}},{"id":2570082,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2021-09-15T20:02:17.000Z","date":"2021-09-13","kind":"exercise","acquired":false,"shares":4250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F17","text":"The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant."}],"balance_after":4250,"derivative":{"exercise_price":273.67,"expiration_date":"2024-01-02","underlying":"Common Stock","underlying_shares":4250},"source":{"system":"sec-edgar","filing":"0001708138-21-000080","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000080/edgardoc.xml","form_type":"4"}},{"id":2570081,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2021-09-15T20:02:17.000Z","date":"2021-09-13","kind":"exercise","acquired":false,"shares":4250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F17","text":"The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant."}],"balance_after":8500,"derivative":{"exercise_price":273.67,"expiration_date":"2024-01-02","underlying":"Common Stock","underlying_shares":4250},"source":{"system":"sec-edgar","filing":"0001708138-21-000080","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000080/edgardoc.xml","form_type":"4"}},{"id":2570080,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-15T20:02:17.000Z","date":"2021-09-13","kind":"sale","acquired":false,"shares":139,"price":652.26,"value":90664.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":2078,"source":{"system":"sec-edgar","filing":"0001708138-21-000080","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000080/edgardoc.xml","form_type":"4"}},{"id":2570079,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-15T20:02:17.000Z","date":"2021-09-13","kind":"sale","acquired":false,"shares":249,"price":651.54,"value":162233.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F16","text":"Represents volume-weighted average price of sales of 249 shares of Company stock on September 13, 2021 at prices ranging from $651.10 to $651.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 13, 2021 at each separate price."}],"balance_after":2217,"source":{"system":"sec-edgar","filing":"0001708138-21-000080","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000080/edgardoc.xml","form_type":"4"}},{"id":2570078,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-15T20:02:17.000Z","date":"2021-09-13","kind":"sale","acquired":false,"shares":56,"price":650.33,"value":36418.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":2466,"source":{"system":"sec-edgar","filing":"0001708138-21-000080","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000080/edgardoc.xml","form_type":"4"}},{"id":2570077,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-15T20:02:17.000Z","date":"2021-09-13","kind":"sale","acquired":false,"shares":124,"price":649.35,"value":80519.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"Represents volume-weighted average price of sales of 124 shares of Company stock on September 13, 2021 at prices ranging from $649.27 to $649.43. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 13, 2021 at each separate price."}],"balance_after":2522,"source":{"system":"sec-edgar","filing":"0001708138-21-000080","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000080/edgardoc.xml","form_type":"4"}},{"id":2570076,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-15T20:02:17.000Z","date":"2021-09-13","kind":"sale","acquired":false,"shares":381,"price":648.25,"value":246983.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"Represents volume-weighted average price of sales of 381 shares of Company stock on September 13, 2021 at prices ranging from $648.06 to $648.58. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 13, 2021 at each separate price."}],"balance_after":2646,"source":{"system":"sec-edgar","filing":"0001708138-21-000080","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000080/edgardoc.xml","form_type":"4"}},{"id":2570075,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-15T20:02:17.000Z","date":"2021-09-13","kind":"sale","acquired":false,"shares":425,"price":647.39,"value":275140.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"Represents volume-weighted average price of sales of 425 shares of Company stock on September 13, 2021 at prices ranging from $647.06 to $647.67. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 13, 2021 at each separate price."}],"balance_after":3027,"source":{"system":"sec-edgar","filing":"0001708138-21-000080","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000080/edgardoc.xml","form_type":"4"}},{"id":2570074,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-15T20:02:17.000Z","date":"2021-09-13","kind":"sale","acquired":false,"shares":354,"price":646.24,"value":228768.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Represents volume-weighted average price of sales of 354 shares of Company stock on September 13, 2021 at prices ranging from $646.04 to $646.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 13, 2021 at each separate price."}],"balance_after":3452,"source":{"system":"sec-edgar","filing":"0001708138-21-000080","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000080/edgardoc.xml","form_type":"4"}},{"id":2570073,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-15T20:02:17.000Z","date":"2021-09-13","kind":"sale","acquired":false,"shares":61,"price":645.21,"value":39357.81,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Represents volume-weighted average price of sales of 61 shares of Company stock on September 13, 2021 at prices ranging from $645.21 to $645.49. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 13, 2021 at each separate price."}],"balance_after":3806,"source":{"system":"sec-edgar","filing":"0001708138-21-000080","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000080/edgardoc.xml","form_type":"4"}},{"id":2570072,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-15T20:02:17.000Z","date":"2021-09-13","kind":"sale","acquired":false,"shares":844,"price":644.52,"value":543974.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents volume-weighted average price of sales of 844 shares of Company stock on September 13, 2021 at prices ranging from $644.03 to $644.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 13, 2021 at each separate price."}],"balance_after":3867,"source":{"system":"sec-edgar","filing":"0001708138-21-000080","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000080/edgardoc.xml","form_type":"4"}},{"id":2570071,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-15T20:02:17.000Z","date":"2021-09-13","kind":"sale","acquired":false,"shares":1549,"price":643.33,"value":996518.17,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents volume-weighted average price of sales of 1,549 shares of Company stock on September 13, 2021 at prices ranging from $643.01 to $643.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 13, 2021 at each separate price."}],"balance_after":4711,"source":{"system":"sec-edgar","filing":"0001708138-21-000080","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000080/edgardoc.xml","form_type":"4"}},{"id":2570070,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-15T20:02:17.000Z","date":"2021-09-13","kind":"sale","acquired":false,"shares":1645,"price":642.54,"value":1056978.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents volume-weighted average price of sales of 1,645 shares of Company stock on September 13, 2021 at prices ranging from $642.00 to $642.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 13, 2021 at each separate price."}],"balance_after":6260,"source":{"system":"sec-edgar","filing":"0001708138-21-000080","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000080/edgardoc.xml","form_type":"4"}},{"id":2570069,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-15T20:02:17.000Z","date":"2021-09-13","kind":"sale","acquired":false,"shares":952,"price":641.56,"value":610765.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents volume-weighted average price of sales of 952 shares of Company stock on September 13, 2021 at prices ranging from $641.01 to $641.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 13, 2021 at each separate price."}],"balance_after":7905,"source":{"system":"sec-edgar","filing":"0001708138-21-000080","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000080/edgardoc.xml","form_type":"4"}},{"id":2570068,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-15T20:02:17.000Z","date":"2021-09-13","kind":"sale","acquired":false,"shares":981,"price":640.61,"value":628438.41,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents volume-weighted average price of sales of 981 shares of Company stock on September 13, 2021 at prices ranging from $640.18 to $640.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 13, 2021 at each separate price."}],"balance_after":8857,"source":{"system":"sec-edgar","filing":"0001708138-21-000080","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000080/edgardoc.xml","form_type":"4"}},{"id":2570067,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-15T20:02:17.000Z","date":"2021-09-13","kind":"sale","acquired":false,"shares":1260,"price":639.45,"value":805707.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents volume-weighted average price of sales of 1,260 shares of Company stock on September 13, 2021 at prices ranging from $639.00 to $639.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 13, 2021 at each separate price."}],"balance_after":9838,"source":{"system":"sec-edgar","filing":"0001708138-21-000080","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000080/edgardoc.xml","form_type":"4"}},{"id":2570066,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-15T20:02:17.000Z","date":"2021-09-13","kind":"sale","acquired":false,"shares":2098,"price":638.46,"value":1339489.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents volume-weighted average price of sales of 2,098 shares of Company stock on September 13, 2021 at prices ranging from $638.00 to $638.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 13, 2021 at each separate price."}],"balance_after":11098,"source":{"system":"sec-edgar","filing":"0001708138-21-000080","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000080/edgardoc.xml","form_type":"4"}},{"id":2570065,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-15T20:02:17.000Z","date":"2021-09-13","kind":"sale","acquired":false,"shares":816,"price":637.71,"value":520371.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents volume-weighted average price of sales of 816 shares of Company stock on September 13, 2021 at prices ranging from $637.26 to $637.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 13, 2021 at each separate price."}],"balance_after":13196,"source":{"system":"sec-edgar","filing":"0001708138-21-000080","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000080/edgardoc.xml","form_type":"4"}},{"id":2570064,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-15T20:02:17.000Z","date":"2021-09-13","kind":"sale","acquired":false,"shares":816,"price":636.64,"value":519498.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 816 shares of Company stock on September 13, 2021 at prices ranging from $636.08 to $636.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 13, 2021 at each separate price."}],"balance_after":14012,"source":{"system":"sec-edgar","filing":"0001708138-21-000080","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000080/edgardoc.xml","form_type":"4"}},{"id":2570063,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":16404,"kind":"person","name":"Tessier-Lavigne Marc","position":1,"cik":"0001437435","reported_name":"Tessier-Lavigne Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-15T20:02:17.000Z","date":"2021-09-13","kind":"exercise","acquired":true,"shares":4250,"price":273.67,"value":1163097.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":14828,"source":{"system":"sec-edgar","filing":"0001708138-21-000080","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813821000080/edgardoc.xml","form_type":"4"}}],"next_cursor":"2021-09-15T20:02:17.000000Z,2570063"}